Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Cytokinetics Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018
Cash and cash equivalents	99,692)	68,639)	101,616)	65,582)	106,238)	93,631)	115,422)	112,666)	90,562)	37,154)	44,594)	82,985)	200,812)	61,134)	49,776)	36,433)	39,634)	34,361)	39,409)	42,256)	27,624)	46,955)	115,011)
Short-term investments	439,547)	497,083)	562,346)	716,995)	761,426)	492,395)	493,552)	358,972)	387,074)	313,147)	380,983)	381,075)	209,452)	151,929)	170,930)	188,679)	126,405)	138,507)	137,213)	156,475)	182,686)	184,986)	136,443)
Accounts receivable	2,499)	985)	1,006)	147)	2,294)	1,973)	6,056)	51,819)	644)	2,701)	4,514)	4,420)	4,965)	2,254)	2,704)	5,163)	6,576)	8,993)	4,165)	2,231)	9,156)	236)	37)
Contract assets	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	575)	2,472)	4,554)	5,876)	10,375)	18,550)
Prepaid expenses and other current assets	19,678)	19,868)	15,661)	12,462)	14,317)	14,251)	8,496)	12,215)	16,661)	11,227)	3,026)	5,741)	3,183)	3,637)	2,528)	3,477)	3,920)	2,515)	3,141)	2,158)	1,927)	1,677)	2,298)
Current assets	561,416)	586,575)	680,629)	795,186)	884,275)	602,250)	623,526)	535,672)	494,941)	364,229)	433,117)	474,221)	418,412)	218,954)	225,938)	233,752)	176,535)	184,951)	186,400)	207,674)	227,269)	244,229)	272,339)
Long-term investments	15,468)	26,871)	40,406)	46,708)	28,544)	10,668)	77,083)	152,050)	191,295)	73,672)	34,664)	36,954)	40,958)	—)	16,510)	42,650)	—)	2,254)	—)	—)	—)	—)	4,015)
Property and equipment, net	75,614)	77,248)	78,859)	80,453)	80,302)	78,586)	75,740)	73,271)	53,896)	36,942)	23,198)	13,346)	7,667)	5,611)	5,162)	4,530)	3,615)	2,945)	3,175)	3,204)	2,687)	2,598)	3,156)
Operating lease right-of-use assets	79,929)	80,866)	81,802)	82,737)	75,076)	72,161)	72,646)	73,138)	80,725)	83,006)	79,687)	2,924)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Other assets	8,187)	8,339)	8,119)	9,691)	7,764)	8,052)	7,258)	7,188)	6,682)	6,453)	6,396)	6,358)	7,075)	7,930)	8,972)	8,882)	7,243)	8,068)	9,036)	300)	323)	412)	416)
Non-current assets	179,198)	193,324)	209,186)	219,589)	191,686)	169,467)	232,727)	305,647)	332,598)	200,073)	143,945)	59,582)	55,700)	13,541)	30,644)	56,062)	10,858)	13,267)	12,211)	3,504)	3,010)	3,010)	7,587)
Total assets	740,614)	779,899)	889,815)	1,014,775)	1,075,961)	771,717)	856,253)	841,319)	827,539)	564,302)	577,062)	533,803)	474,112)	232,495)	256,582)	289,814)	187,393)	198,218)	198,611)	211,178)	230,279)	247,239)	279,926)

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Cytokinetics Inc. current assets decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Property and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Cytokinetics Inc. property and equipment, net decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Non-current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Cytokinetics Inc. non-current assets decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Cytokinetics Inc. total assets decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Cytokinetics Inc. cash and cash equivalents decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 not reaching Q1 2023 level.
Short-term investments	Amount of investment in marketable security, classified as current.	Cytokinetics Inc. short-term investments decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Accounts receivable	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Cytokinetics Inc. accounts receivable decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 exceeding Q1 2023 level.

Cytokinetics Inc. (NASDAQ:CYTK)

Balance Sheet: AssetsQuarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data